Judi Health Highlights Growing PBM Regulatory Reforms and Positions Itself as Policy-Focused Partner

Judi Health has shared an update. The company reported that its General Counsel & Chief Compliance Officer, Lloyd Fiorini, recently spoke alongside the Deputy General Counsel of Prime Therapeutics, Anthony Palmisano Jr., at an American Bar Association national managed care institute conference. The discussion focused on ongoing reforms in pharmacy benefit management (PBM), including changes in pricing structures, rebate practices, transparency, and regulatory oversight. Judi Health also highlighted its latest “Policy Pulse” publication, which outlines five PBM practices currently being targeted by lawmakers across the U.S.

For investors, this update underscores the accelerating regulatory shift around PBMs—a core component of drug pricing and reimbursement in the U.S. healthcare system. Heightened scrutiny of rebates, pricing transparency, and compliance requirements could materially affect margins and operating models for PBMs and affiliated healthcare technology or services firms. Judi Health’s active engagement in policy analysis and industry discussions suggests it aims to position itself as a knowledgeable partner in navigating regulatory changes, which may enhance its credibility with payers, providers, and potential enterprise customers. If the company’s products or services help clients adapt to new PBM rules, demand could increase as reforms progress, potentially supporting revenue growth and strengthening its competitive position within healthcare technology and managed care ecosystems. However, the ultimate financial impact will depend on the final shape and timing of PBM regulations and Judi Health’s ability to convert its policy expertise into scalable commercial offerings.